Neurol. praxi 2018; 19(Suppl.1): 19-21 | DOI: 10.36290/neu.2018.144

Phytopharmacology of standardized Ginkgo biloba leaf extract (EGb 761)

PharmDr. MVDr. Vilma Vranová, Ph.D.
Ústav aplikované farmacie, Brno

In recent years, the standardized EGb 761 extract has been one of the most commonly clinically tested and most frequently prescribedphytopharmaceuticals in Europe, being registered as a medication in 72 countries. There is a multitude of preparations inthe market, ranging from registered medications with a precisely defined composition to products of untraceable manufacturerswith virtually unknown composition. Medications with EGb 761 are primarily intended to treat mild cognitive disorder, mild dementiaof the Alzheimer type, vascular dementias, and mixed dementias. Clinical trials show that the use of standardized Ginkgobiloba extract is safe and the occurrence of adverse effects is rare.

Keywords: Ginkgo biloba, EGb 761, ginkgolic acid, falsification

Published: August 1, 2018  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Vranová V. Phytopharmacology of standardized Ginkgo biloba leaf extract (EGb 761). Neurol. praxi. 2018;19(Demence - strašák 21. století):19-21. doi: 10.36290/neu.2018.144.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. European Medines Agency (HMPC 2014) Assessment report on Ginkgo biloba L., folium. Dostupné na http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/herbal/medicines/herbal_med_000105.jsp&mid=WC0b01ac058001fa1d.
    2. van Beek TA, Montoro P. Chemical analysis and quality control of Ginkgo biloba leaves, extracts, and phytopharmaceuticals. J Chromatogr A. 2009; 1216 (11): 2002-2032. Go to original source... Go to PubMed...
    3. Bone KM. Potential interaction of Ginkgo biloba leaf with antiplatelet or anticoagulant drugs: What is the evidence? Mol Nutr Food Res. 2008; 52(7): 764-771. Go to original source... Go to PubMed...
    4. Fišar HR. Úloha mitochondrií v mechanismech synaptické plasticity, buněčného poškození a poruch nálady. Čes a slov Psychiat. 2011; 107(1): 14-27.
    5. Gaus W, Westendrof J, Diebow R, Kieser M. Identification of adverse drug reactions by evaluation of a prescription database, demonstrated for risk of bleeding. Methods Inf Med. 2005; 44(5): 697-703. Go to original source...
    6. Hermann R, von Richter O. Clinical evidence of herbal drugs as perpetrators of pharmacokinetic drug interactions. Planta Med. 2012; 78: 1458-1477. Go to original source... Go to PubMed...
    7. Jirák R. Poruchy paměti - základní přehled. Medicína po promoci 2011; 6.
    8. Kellermann AJ, Kloft C. Is there a risk of bleeding associated with standardized ginkgo biloba extract therapy? A systematic review and meta-analysis. Pharmacotherapy 2011; 31(5): 490-502. Go to original source... Go to PubMed...
    9. Mazza M. Ginkgo biloba and donepezil: a comparison in the treatment of Alzheimer's dementia in a randomized placebo-controlled double-blind study. European Journal of Neurology 2006; 13: 981-985. Go to original source... Go to PubMed...
    10. Ministerstvo zemědělství České republiky. Doplňky stravy. Pravidla pro uvádění na trh a splnění informační povinnosti. [online] [cit. 2017-11-15]. Dostupné z http://eagri.cz/public/web/mze/potraviny/legislativa/doplnky-stravy).
    11. Smith RA, Hartley RC, Cocheme HM, Murphy MP. Mitochondrial pharmacology. Trends in Pharmacological Sciences 2002; 21(6): 341-352. Go to original source... Go to PubMed...
    12. Státní ústav pro kontrolu léčiv. Informační zpravodaj. Nežádoucí účinky léčiv [online] [cit. 2017-11-15]. Dostupné z http://www.sukl.cz/sukl/informacni-zpravodaj-nezadouci-ucinky-leciv-3-2017?highlightWords=ginkgo.
    13. Tan MS, Yu JT, Tan CC, Wang HF, Meng XF, Wang C, Jiang T, Zhu XC, Tan L. Efficacy and adverse effects of Ginkgo biloba for cognitive impairment and dementia: A systematic review and Meta-analysis. Journal of Alzheimer's disease 2015; (43(2): 589-603. Go to original source... Go to PubMed...
    14. Tawab M, Krzywon M, Schubert-Zsilavecz M. Dietary supplements with Ginkgo under the microscope. Pharm. Ztg. 2010; 20: 62-67.
    15. Tůmová B. Ginkgo biloba - interakce s ostatními léky. Prakt. Lékárenství 2006; (2(5): 229-230.
    16. Ude C, Schubert-Zsilavecz M, Wurglics M. Ginkgo biloba extracts: a review of the pharmacokinetics of the active ingredients. Clin Pharmacokinet. 2013; 52(9): 727-749. Go to original source... Go to PubMed...
    17. Unger M. Pharmacokinetic drug interactions involving Ginkgo biloba. Drug Metab Rev. 2013; 45(3): 353-385. Go to original source... Go to PubMed...
    18. Vellas B, Coley N, Ousset PJ, Berrut G, Dartigues JF, Dubois B, Grandjean H, Pasquier F, Piette F, Robert P, Touchon J, Garnier P, Mathiex-Fortunet H, Andrieu S; GuidAge Study Group. Long-term use of standardised ginkgo biloba extract for the prevention of Alzheimer's dinase (guidage): a randomised, placebo-controlled trial. Lancet Neuro. 2012; 11(10): 851-859. Go to original source... Go to PubMed...
    19. Wanwimolruk S, Prachayasittikul V. Cytochrome P450 enzyme mediated herbal drug interactions (Part 1) Excli Journal 2014; 13: 347-391. Go to PubMed...
    20. White HL, Scates PW, Cooper BR. Extracts of Gingko biloba leaves inhibits monoamine oxidas. Life Sci 1996; 58(16): 1315. Go to original source... Go to PubMed...
    21. Zadoyan G, Rokitta D, Klement S, Dienel A, Hoerr R, Gramatté T, Fuhr U. Effect of Ginkgo biloba special extract EGb 761(R) on human cytochrome P450 activity: a cocktail interaction study in healthy volunteers. Eur J Clin Pharmacol. 2012; 68: 553-560. Go to original source... Go to PubMed...

    Return to the content


    Neurology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.